iud with levonorgestrel health risks

LidoSite uses an active transdermal delivery technology known as iontophoresis,which administers medications through the skin via a mild electric current iud with levonorgestrel health risks. The LidoSite system administers lidocaine and epinepherine using a patentedelectrotransport technology that enables the controlled delivery of medicationover a predetermined period of time, from minutes to days iud with levonorgestrel health risks. Topical anestheticcreams and patches can take up to an hour to numb the skin, while LidoSite worksin 10 minutes iud with levonorgestrel health risks. This product has successfully completed clinical trials and hasbeen found to significantly decrease pain from needle injections and similarprocedures in both adults and children iud with levonorgestrel health risks. Lidosite is intended to also addressa strong need in adult applications iud with levonorgestrel health risks. Its major impact is expected to be in thepediatric population, where pain associated with needlesticks, blood-draw proceduresand immunizations is a major issue for the clinician, child and parent.

Studies Demonstrate Safety and Efficacy
More than 1,000 adults and children (ages 5 to 17 years) participated in clinicalstudies evaluating the safety and efficacy of the Vyteris system in providingtopical anesthesia iud with levonorgestrel health risks. Two pivotal studies compared the system (administering lidocaine10% and epinephrine 0.1%) with placebo for use prior to needle injections orintravenous (IV) insertions iud with levonorgestrel health risks. Additional studies evaluated the efficacy of thesystem for use prior to the removal of surface skin lesions (via incision orlaser treatment) iud with levonorgestrel health risks. Patients treated with Vyteris' LidoSite system experiencedsignificantly less pain associated with needlestick procedures compared withsubjects treated with the placebo system iud with levonorgestrel health risks. Consequently, fewer patients in theactive group reported experiencing severe pain and most reported feeling littleor no pain in contrast to patients in the placebo group iud with levonorgestrel health risks. In these studies, thepatients were evaluated using established pain assessment tools including theFacial Affective Scale (FAS) (A = no pain, I = maximal pain) or the Visual AnalogueScale (VAS) (0 = no pain, 10 = maximal pain) methods iud with levonorgestrel health risks. Evaluations were takenimmediately following patch removal and at 24 hours for side effects iud with levonorgestrel health risks. Pain scoreevaluations from both scales resulted in statistically significantly less painfor those who used the Vyteris' LidoSite system, as compared to placebo iud with levonorgestrel health risks. Inthese studies, the most common side effect was mild erythema (skin redness),which disappeared for most patients within 24-hours.

Copyright 2005 D-S LTD.
All Rights Reserved.